We are joined by Petra Langerbeins at the EHA annual meeting in Amsterdam to discuss her presentation on ibrutinib versus placebo in patients with asymptomatic, treatment-naive early-stage chronic lymphocytic leukaemia (CLL): primary endpoint results of the phase III double-blind randomised CLL12 trial.
Questions
1. What is the current treatment paradigm for patients with asymptomatic early-stage chronic lymphocytic leukaemia (CLL)? (0:05)
2. What are the limitations of available treatment options for people with asymptomatic high-risk CLL? (0:30)
3. Could you tell us a little about the findings of the phase III study of ibrutinib in this treatment setting? (1:06)
4. Which patients are most likely to respond to ibrutinib and in which is it contraindicated? (2:50)
5. What is the safety profile of ibrutinib and how can adverse events be managed? (3:55)
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
